A randomized, placebo-controlled, phase I/II study of tivantinib (ARQ 197) in combination with cetuximab and irinotecan in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (CRC) who had received previous front-line systemic therapy.

被引：0
|
作者：
Eng, Cathy
Hart, Lowell L.
Severtsev, Aleksey
Gladkov, Oleg
Mueller, Lothar
Kopp, Mikhail V.
Vladimirov, Vladimir Ivanovich
Langdon, Robert M.
Kotiv, Bogdan
Barni, Sandro
Hsu, Ching
Bolotin, Ellen
Von Roemeling, Reinhard
Schwartz, Brian E.
Bendell, Johanna C.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Florida Canc Specialists SCRI, Ft Myers, FL USA
[3] Cent Clin Hosp 1 OAO, Moscow, Russia
[4] Chelyabinsk Reg Clin Oncol Ctr, Chelyabinsk, Russia
[5] Samara Reg Clin Oncol Dispensary, Samara, Russia
[6] State Med Inst Pyatigorsk, Pyatigorsk, Russia
[7] Nebraska Methodist Hosp, Omaha, NE USA
[8] State Educ Inst, High Profess Educ Mil Med Acad Named SM Kirov, St Petersburg, Russia
[9] Div Oncol, Treviglio, Italy
[10] Daiichi Sankyo Co Ltd, Edison, NJ USA
[11] ArQule Inc, Woburn, MA USA
[12] Sarah Cannon Res Inst, Nashville, TN USA
[13] Tennessee Oncol, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3508
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy
    Eng, Cathy
    Bessudo, Alberto
    Hart, Lowell L.
    Severtsev, Aleksey
    Gladkov, Oleg
    Mueller, Lothar
    Kopp, Mikhail V.
    Vladimirov, Vladimir
    Langdon, Robert
    Kotiv, Bogdan
    Barni, Sandro
    Hsu, Ching
    Bolotin, Ellen
    von Roemeling, Reinhard
    Schwartz, Brian
    Bendell, Johanna C.
    INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (01) : 177 - 186
  • [2] Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-Met inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy
    Eng, C.
    Bendell, J. C.
    Bessudo, A.
    Gabrail, N. Y.
    Diamond, J.
    Pande, A. U.
    Gorbatchevsky, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [3] Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-MET inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy
    Bessudo, A.
    Bendell, J. C.
    Gabrail, N.
    Kopp, M. V.
    Mueller, L.
    Hart, L. L.
    Vladimirov, V. I.
    Pande, A. U.
    Gorbatchevsky, I.
    Eng, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] PHASE I/II STUDY OF TIVANTINIB (ARQ 197) IRINOTECAN, AND CETUXIMAB IN PATIENTS WITH KRAS WILDTYPE, PREVIOUSLY TREATED, METASTATIC COLORECTAL CANCER
    Eng, Cathy
    Alberto, Bessudo
    Gabrail, Nashat
    Lopez, Taina
    Zahir, Hamim
    von Roemeling, Reinhard
    Bendell, Johanna
    ANNALS OF ONCOLOGY, 2012, 23 : 24 - 25
  • [5] A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer
    Sclafani, Francesco
    Kim, Tae Y.
    Cunningham, David
    Kim, Tae W.
    Tabernero, Josep
    Schmoll, Hans J.
    Roh, Jae K.
    Kim, Sun Y.
    Park, Young S.
    Guren, Tormod K.
    Hawkes, Eliza
    Clarke, Steven J.
    Ferry, David
    Frodin, Jan-Erik
    Ayers, Mark
    Nebozhyn, Michael
    Peckitt, Clare
    Loboda, Andrey
    Mauro, David J.
    Watkins, David J.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (12):
  • [6] RE: A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer
    He Wen-zhuo
    Xia Liang-ping
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (03):
  • [7] Phase II study of tivantinib (ARQ 197) and cetuximab in patients with EGFR inhibitor-resistant, MET-High, KRAS wild-type (KRASwt) metastatic colorectal cancer (mCRC)
    Lorenza, Rimassa
    Silvia, Bozzarelli
    Stefano, Cordio
    Filippo, Pietrantonio
    Laura, Toppo
    Sara, Lonardi
    Alberto, Zaniboni
    Roberto, Bordonaro
    Maria, Di Bartolomeo
    Wanda, Liguigli
    Vittorina, Zagonel
    Chiara, Tronconi Maria
    Luca, Di Tommaso
    Laura, Giordano
    Armando, Santoro
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer
    Garrido-Laguna, I.
    McGregor, K. A.
    Wade, M.
    Weis, J.
    Gilcrease, W.
    Burr, L.
    Soldi, R.
    Jakubowski, L.
    Davidson, C.
    Morrell, G.
    Olpin, J. D.
    Boucher, K.
    Jones, D.
    Sharma, S.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) : 1257 - 1264
  • [9] A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer
    I. Garrido-Laguna
    K. A. McGregor
    M. Wade
    J. Weis
    W. Gilcrease
    L. Burr
    R. Soldi
    L. Jakubowski
    C. Davidson
    G. Morrell
    J. D. Olpin
    K. Boucher
    D. Jones
    S. Sharma
    Investigational New Drugs, 2013, 31 : 1257 - 1264
  • [10] PHASE II STUDY OF COMBINATION THERAPY WITH S-1 AND CETUXIMAB IN PATIENTS WITH KRAS WILD-TYPE UNRESECTABLE COLORECTAL CANCER, WHO HAD PREVIOUSLY RECEIVED IRINOTECAN, OXALIPLATIN, AND FLUOROPYRIMIDINES (KSCC0901)
    Kitazono, M.
    Kobayashi, K.
    Emi, Y.
    Kakechi, Y.
    Takahashi, T.
    Akagi, Y.
    Tuji, A.
    Yoshida, K.
    Baba, H.
    Ogata, H.
    Shimokawa, M.
    Natsugoe, S.
    Maehara, Y.
    ANNALS OF ONCOLOGY, 2012, 23 : 122 - 122
12345